Laxmi Organic Industries receives factory license for new manufacturing site in Gujarat
Laxmi Organic Industries Limited has recently informed exchanges that the company obtained a factory license from the Directorate of Industrial Safety and Health, Gujarat. The license is issued under the Factories Act for the company's upcoming synthetic organic chemicals manufacturing facility located at Dahej, Village Jolva and Vadadala, District Bharuch, Gujarat.
The newly issued factory license is a mandatory regulatory approval required to initiate manufacturing operations at the site. With this development, the company moves a step closer to commencing production activities at its new plant.
This approval is part of the standard compliance process and holds operational significance for Laxmi Organic's expansion strategy in the chemical manufacturing sector.
The grant of this license marks a key operational milestone, enabling the company to proceed with commissioning and production activities at the Dahej site. The site is expected to enhance the company's manufacturing capabilities and support future growth in domestic and international markets.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
35 minutes ago
- Business Upturn
Sika Interplant Systems shares surge 12% following license agreement with Collins Aerospace
By Aman Shukla Published on June 3, 2025, 09:42 IST Sika Interplant Systems (SIKA) shares soared 12% following the announcement of a significant License Agreement with Goodrich Actuation Systems SAS (France) and Goodrich Actuation Systems Limited (UK), both part of Collins Aerospace. As of 9:41 AM, the shares were trading 11.20% higter at Rs 918.05. Under this strategic agreement, SIKA gains the license to perform maintenance, repair, and overhaul (MRO) of specific primary flight control actuation components manufactured by Collins Aerospace. These critical components are standard installations on all Airbus A320 and A321 series aircraft, widely used in commercial aviation. The License Agreement authorizes SIKA to service these components for aircraft registered in India and select neighboring countries, strengthening SIKA's regional footprint in aerospace MRO services. This collaboration supports SIKA's growth strategy to expand its MRO capabilities and offer enhanced support to aviation customers across India and the surrounding region. Market analysts view this partnership as a positive move for SIKA, positioning the company to capture a larger share of the aerospace MRO market amid growing demand for cost-effective aircraft maintenance solutions. Sika Interplant Systems continues to build on its reputation as a trusted aerospace service provider, leveraging this collaboration to deliver high-quality maintenance solutions aligned with global OEM standards. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
35 minutes ago
- Business Upturn
Apeejay Surrendra shares jump 3% after signing hotel management agreement in Mathura
By Aman Shukla Published on June 3, 2025, 09:48 IST Apeejay Surrendra Hospitality Ltd shares surged by 3% in early morning trading after the company announced a significant new hotel management agreement. The firm signed a contract with Goyal Parmarthik Trust to manage the upcoming luxury property, Zone by THE PARK, located in Aanyor, Tehsil Govardhan, Mathura, Uttar Pradesh. The new hotel is set to feature approximately 100 well-appointed rooms along with a range of premium amenities. These include a banquet hall, conference rooms, an all-day dining restaurant, swimming pool, gymnasium, spa facilities, ample parking, elevators, and dedicated office space for hotel management. This expansion is expected to strengthen Apeejay Surrendra's presence in the growing hospitality market of Uttar Pradesh. Currently, Apeejay Surrendra operates 35 hotels across India through a mix of owned, leased, and managed properties. The addition of Zone by THE PARK, Mathura will enhance the company's portfolio in the mid-to-luxury segment, reinforcing its commitment to delivering high-quality hospitality experiences. The company's strategic growth through hotel management agreements aligns with its goal to capitalize on rising domestic tourism and business travel in India. Investors responded positively to the announcement, reflecting confidence in Apeejay Surrendra's expansion plans and long-term prospects. Apeejay Surrendra shares opened at ₹153.50 today, hitting a high of ₹156.06 and a low of ₹150.49 during trading. The stock remains volatile, with a 52-week high of ₹206.20 and a low of ₹129.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
13 hours ago
- Business Upturn
Biocon receives CDSCO approval for its Liraglutide drug in India
Biocon Limited, a global biopharmaceutical company, has announced that it has received regulatory approval in India for its Liraglutide drug substance. Its wholly owned subsidiary, Biocon Pharma Limited, has also secured approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge) from the Central Drugs Standard Control Organisation (CDSCO). The product is a generic version of Victoza®, used as an adjunct to diet and exercise to improve glycemic control in adults, adolescents, and children aged 10 years and older with Type 2 Diabetes Mellitus that is not adequately managed. Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, commented, 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India'' This approval was granted under the CDSCO's recently introduced 101 route. This regulatory pathway allows for the recognition of approvals issued by referenced and established foreign regulatory agencies, thereby facilitating faster access to critical medicines in India. Glucagon-like peptide-1 (GLP-1) therapies, including Liraglutide, are being recognized as a growing segment in diabetes management. Biocon has stated its intent to expand its portfolio in this category as part of its future business strategy. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
